{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:57:02Z","timestamp":1786993022688,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jnci.2017.05.001","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T12:17:45Z","timestamp":1503577065000},"page":"155-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy"],"prefix":"10.1186","volume":"29","author":[{"given":"Raafat","family":"Abdel-Malek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrillus S.","family":"Shohdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal S.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezzat","family":"Safwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jnci.2017.05.001_b0005","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jjco\/29.1.33","article-title":"ESHAP as salvage therapy for refractory non-Hodgkin\u2019s lymphoma: Taiwan experience","volume":"29","author":"Wang","year":"1999","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0015","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0020","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","article-title":"Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy","volume":"21","author":"Olver","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0025","first-page":"2837","article-title":"Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study","volume":"24","author":"Adra","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0030","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(06)70668-4","article-title":"Rituximab for early-stage diff use large-B-cell lymphoma","volume":"7","author":"Friedberg","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/BF00365579","article-title":"Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists","volume":"2","author":"Hesketh","year":"1994","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0045","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.1998.16.3.1174","article-title":"Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group","volume":"16","author":"Latreille","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1023\/A:1008256115221","article-title":"Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study","volume":"9","author":"Goedhals","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0055","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/S0959-8049(01)00326-4","article-title":"Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis","volume":"37","author":"Tsukada","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0060","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Gr","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12906-015-0556-0","article-title":"Anti-emetic mechanisms of Zingiber officinale against cisplatin induced emesis in the pigeon; behavioral and neurochemical correlates","volume":"15","author":"Ullah","year":"2015","journal-title":"BMC Complement Altern Med"},{"key":"10.1016\/j.jnci.2017.05.001_b0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/acupmed-2015-010833","article-title":"Electroacupuncture alleviates cisplatin-induced nausea in rats","volume":"34","author":"Cui","year":"2016","journal-title":"Acupunct Med"},{"key":"10.1016\/j.jnci.2017.05.001_b0075","doi-asserted-by":"crossref","first-page":"943618","DOI":"10.1155\/2015\/943618","article-title":"Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy","volume":"2015","author":"Ranganath","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jnci.2017.05.001_b0080","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","article-title":"Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin co","volume":"30","author":"Albany","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0085","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00520-014-2182-7","article-title":"Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy","volume":"22","author":"Hamada","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0090","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00520-015-2856-9","article-title":"Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy","volume":"24","author":"Ando","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0095","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"24","author":"Saito","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3892\/mco.2016.769","article-title":"Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: a retrospective comparison","volume":"4","author":"Tsuda","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0105","article-title":"Aprepitant in multiple-day cisplatin-based chemotherapy","volume":"30","author":"Freve","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2017.05.001_b0110","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00520-015-2944-x","article-title":"Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors","volume":"24","author":"Dranitsaris","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jnci.2017.05.001_b0115","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/bjc.1998.244","article-title":"Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles","volume":"77","author":"de Wit","year":"1998","journal-title":"Br J Cancer"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036217300304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036217300304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T09:40:18Z","timestamp":1558604418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036217300304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1110036217300304"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2017.05.001","relation":{},"ISSN":["1110-0362"],"issn-type":[{"value":"1110-0362","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Egyptian National Cancer Institute","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnci.2017.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.","name":"copyright","label":"Copyright"}]}}